Announcements Trials
Browse Landscape

Status

Completed 22Active not recruiting 9Withdrawn 5Terminated 3No longer available 2Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Expanded_access 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Primary Myelofibrosis 1

Interventions

trametinib 4nilotinib 4elotuzumab 4dabrafenib 4Amifampridine 4regorafenib 3pembrolizumab 3midostaurin 3fludarabine phosphate 3fludarabine 3Nivolumab 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Cyclophosphamide 3Crizotinib 3Bortezomib 3Axitinib 3venetoclax 2veliparib 2tazemetostat 2talimogene laherparepvec 2navitoclax 2gallium 68 PSMA-11 2ceritinib 2carbon-11 acetate 2aldesleukin 2Whole-Body Irradiation 2Trabectedin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
No longer available × navitoclax × Clear all
NCT05215405 2025-02-03

Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL

University of Texas Southwestern Medical Center

No longer available
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03592576 2024-05-06

Expanded Access to Navitoclax

AbbVie

No longer available
LymphoidMyeloidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡